🎗️ Проект автоматически собирает и публикует онкологические новости из проверенных медицинских источников — 24/7, со ссылкой на первоисточник
Английские новости переводятся автоматически
Главное · Новое

Tumor mutations and immune activity may reveal who benefits from investigational lymphoma drug

Researchers at the University of Tsukuba conducted a physician-initiated phase 2 clinical trial of dasatinib in patients with relapsed or refractory T-follicular helper cell lymphoma (TFHL), an aggressive and difficult-to-treat blood cancer. The study identified genetic alterations and features of the immune…

Medical Xpress: Cancer 44 мин назад Источник ↗

🎗️Лента новостей

Онкология

Immune system protein is a cancer killer on its own, new study shows

For decades, scientists have known that a protein made by T cells and natural killer (NK) cells in the immune system, called perforin, can kill tumor cells by punching a hole in the cell wall and injecting proteases called granzymes, which kill the cell. Now, new work led by researchers at the University of Michigan…

Онкология

Residential fine particulate matter linked to minimal residual disease in pediatric leukemia

For pediatric patients with high-risk B-cell acute lymphoblastic leukemia (B-ALL), residential fine particulate matter (PM₂.₅) concentrations during induction therapy are associated with positive end-of-induction (EOI) minimal residual disease (MRD), according to a study published in JNCI Cancer Spectrum.